for people ages 18 years and up (full criteria)
at San Francisco, California and other locations
study started
estimated completion:



Phase 3b open-label, multicenter study to evaluate the safety and efficacy of avatrombopag in subjects with thrombocytopenia scheduled for operations to critical sites or operations with a high risk of bleeding.

Official Title

An Open-Label Study to Evaluate the Efficacy and Safety of Avatrombopag for the Treatment of Subjects With Thrombocytopenia Scheduled for a Surgical Procedure


Subjects will receive oral avatrombopag once daily for 5 days beginning on Day 1, followed by a wait period prior to the procedure, which will occur on Day 10 to 13. The Follow-up Period will include 2 visits; 7 days post-procedure and 30 days after last dose.


Thrombocytopenia low platelet count ITP Avatrombopag 60 mg


You can join if…

Open to people ages 18 years and up

  • Men and women greater than or equal to 18 years of age;
  • A mean baseline platelet count between:
  • 50 × 109/L and <100 × 109/L for non-chronic liver disease participants

  • 50 × 109/L and <75 × 109/L for participants with chronic liver disease;

  • Participant is scheduled to undergo operations to critical sites (eg, eye surgery,neurosurgery) or operations with a high risk of bleeding (eg, major abdominal surgery), or, in the opinion of the Investigator, would otherwise require a pre-operative platelet transfusion to prevent bleeding

You CAN'T join if...

  • Participant with a history of arterial or venous thrombosis within 6 months of baseline;
  • Participant with known portal vein blood flow velocity rate <10 cm/second or previous portal vein thrombosis within 6 months of baseline;
  • Participant plans to have a platelet transfusion or plans to receive blood products containing platelets within 7 days of the Baseline Visit;
  • Use of erythropoietin-stimulating agents;
  • Participant has a known medical history of genetic prothrombotic syndromes; or
  • Participant has abnormal hemoglobin levels or prothrombin time/international normalized ratio


  • Dova Site not yet accepting patients
    San Francisco California 94143 United States
  • Dova Site accepting new patients
    Reno Nevada 89503 United States


accepting new patients
Start Date
Completion Date
Dova Pharmaceuticals
Phase 3
Study Type
Last Updated